SAG and cancer: Together with our previous work, demonstrating that SAG-SCF E3 ubiquitin ligase is an attractive anti-cancer and radiosensitizing target (for review, see [50], [51], [52], [53]), the small molecule inhibitor of SAG-SCF E3 ligase, such as MLN4924, which is currently under several phase I clinical trials [54], may have multiple applications in the treatment of human cancers.